Ampio Pharmaceuticals, Inc. to Host a Conference Call and Webinar

ENGLEWOOD, Colo.March 2, 2022 — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, announced that the Company will be hosting a webinar and conference call today at 4:30pm EST to provide an update on clinical and regulatory progress in osteoarthritis of the knee.

Webinar Details

Date/TimeMarch 2, 2022, at 4:30 pm EST 
Webinar Link:https://event.on24.com/wcc/r/3574331/964B6C5B80DB9EFD05CA55D0977BD0D5

Canada dial-in number (Toll Free): 1 833 950 0062 
Canada dial-in number (Local): 1 226 828 7575 
United States (Toll Free): 1 833 927 1758 
United States (Local): 1 646 904 5544 
All other locations: +1 929 526 1599 
Access code: 644727

*Participants will need to enter the participant access code before being met by an operator

In order to submit questions, participants must have Internet connectivity, as questions will only be addressed via the webcast. The conference call line will be in listen-only mode.

About Ampio Pharmaceuticals 

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and may be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).

Forward Looking Statements 

Ampio’s statements in this press release and the webinar that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter  into partnering arrangements,  clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Contacts: 
Tony Russo or Nic Johnson 
Russo Partners 
info@ampiopharma.com 
tony.russo@russopartnersllc.com 
nic.johnson@russopartnersllc.com